Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients

Clinical Colorectal Cancer

Volumn 18, Issue 4, 2019, Pages 292-300

  Birkett, Richard T ^a   Chamely, Elias ^a   Concors, Seth J ^a   Bleier, Joshua I ^a   Aarons, Cary B ^a   Shanmugan, Skandan ^a   Saur, Nicole M ^a   Paulson, Emily Carter ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvant chemotherapy; Colon cancer; Stage II; Survival; Young patients

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; COLON CANCER; COLON RESECTION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICATION OVERUSE; OVERALL SURVIVAL; PERINEURAL INVASION; RETROSPECTIVE STUDY; ADENOCARCINOMA; COLON TUMOR; FOLLOW UP; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRESCRIPTION DRUG OVERUSE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE;

EID: 85070889039     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2019.04.002     Document Type: Article

References (26)

1. American Cancer Society: Cancer Facts & Figures. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf, 2018. (Accessed 3 December 2017)
2. Bailey, C.E., Hu, C.Y., You, Y.N., et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg 150 (2015), 17–22.
3. You, Y.N., Xing, Y., Feig, B.W., Chang, G.J., Cormier, J.N., Young-onset colorectal cancer: is it time to pay attention?. Arch Intern Med 172 (2012), 287–289.
4. National Cancer Institute, Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute, National Institutes of Health. Available at: https://seer.cancer.gov/faststats. (Accessed 3 December 2017)
5. Benson, A.B. 3rd, Schrag, D., Somerfield, M.R., et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22 (2004), 3408–3419.
6. Quasar Collaborative Group Gray, R., Barnwell, J., McConkey, C., Hills, R.K., Williams, N.S., Kerr, D.J., Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (2007), 2020–2029.
7. Kuebler, J.P., Wieand, H.S., O'Connell, M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25 (2007), 2198–2204.
8. Wolmark, N., Fisher, B., Rockette, H., et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 80 (1988), 30–36.
9. Mamounas, E., Wieand, S., Wolmark, N., et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17 (1999), 1349–1355.
10. Varghese, A., Chemotherapy for stage II colon cancer. Clin Colon Rectal Surg 28 (2015), 256–261.
11. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International multicentre pooled analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17 (1999), 1356–1363.
12. Gill, S., Loprinzi, C.L., Sargent, D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 (2004), 1797–1806.
13. Wells, K.O., Hawkins, A.T., Krishnamurthy, D.M., et al. Omission of adjuvant chemotherapy is associated with increased mortality in patients with T3N0 colon cancer with inadequate lymph node harvest. Dis Colon Rectum 60 (2017), 15–21.
14. Manjelievskaia, J., Brown, D., McGlynn, K.A., Anderson, W., Shriver, C.D., Zhu, K., Chemotherapy use and survival among young and middle-aged patients with colon cancer. JAMA Surg 152 (2017), 452–459.
15. Kneuertz, P.J., Chang, G.J., Hu, C.Y., et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg 150 (2015), 402–409.
16. Umar, A., Boland, C.R., Terdiman, J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96 (2004), 261–268.
17. O'Connor, E.S., Greenblatt, D.Y., LoConte, N.K., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic feature. J Clin Oncol 25 (2011), 3381–3388.
18. Ribic, C.M., Sargent, D.J., Moore, M.J., et al. Tumor microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003), 247–257.
19. Sargent, D.J., Marsoni, S., Monges, G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28 (2010), 3219–3226.
20. Benson, A.B. 3rd, Venook, A.P., Bekaii-Saab, T., et al., National Comprehensive Cancer Network. Colon cancer, version 3.2014. J Natl Compr Cancer Netw 12 (2014), 1028–1059.
21. Ejaz, A., Casadaban, L., Maker, A.V., Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis. J Surg Res 215 (2017), 12–20.
22. Booth, C.M., Nanji, S., Wei, X., et al. Adjuvant chemotherapy for stage II colon cancer: practice patterns and effectiveness in the general population. Clin Oncol (R Coll Radiol) 29 (2017), e29–e38.
23. Lewis, C., Xun, P., He, K., Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer 24 (2016), 1463–1471.
24. Domati, F., Luppi, G., Reggiani-Bonetti, L., et al. The perception of health-related quality of life in colon cancer patients during chemotherapy: differences between men and women. Intern Emerg Med 10 (2015), 423–429.
25. Wiela-Hojeńska, A., Kowalska, T., Filipczyk-Cisarż, E., Łapiński, Ł, Nartowski, K., Evaluation of the toxicity of anticancer chemotherapy in patients with colon cancer. Adv Clin Exp Med 24 (2015), 103–111.
26. Land, S.R., Kopec, J.A., Cecchini, R.S., et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25 (2007), 2205–2211.